

Imatinib Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/I005A61CCA5EN.html>

Date: February 2018

Pages: 137

Price: US\$ 3,480.00 (Single User License)

ID: I005A61CCA5EN

Abstracts

Report Summary

Imatinib Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Imatinib Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Imatinib Drugs 2013-2017, and development forecast 2018-2023

Main market players of Imatinib Drugs in United States, with company and product introduction, position in the Imatinib Drugs market

Market status and development trend of Imatinib Drugs by types and applications

Cost and profit status of Imatinib Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Imatinib Drugs market as:

United States Imatinib Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Imatinib Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Capsules

Tablets

United States Imatinib Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals

Drug Stores

Other

United States Imatinib Drugs Market: Players Segment Analysis (Company and Product introduction, Imatinib Drugs Sales Volume, Revenue, Price and Gross Margin):

Apotex Inc.

Novartis

Sanofi S.A.

Cipla Inc.

Mylan Pharms Inc.

Glenmark Pharmaceuticals Ltd.

Sun Pharmaceuticals

Actavis Generics

Dr. Reddy's Laboratories

Teva Pharmaceutical Industries Ltd.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF IMATINIB DRUGS

- 1.1 Definition of Imatinib Drugs in This Report
- 1.2 Commercial Types of Imatinib Drugs
 - 1.2.1 Capsules
 - 1.2.2 Tablets
- 1.3 Downstream Application of Imatinib Drugs
 - 1.3.1 Hospitals
 - 1.3.2 Drug Stores
 - 1.3.3 Other
- 1.4 Development History of Imatinib Drugs
- 1.5 Market Status and Trend of Imatinib Drugs 2013-2023
 - 1.5.1 United States Imatinib Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Imatinib Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Imatinib Drugs in United States 2013-2017
- 2.2 Consumption Market of Imatinib Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Imatinib Drugs in United States by Regions
 - 2.2.2 Revenue of Imatinib Drugs in United States by Regions
- 2.3 Market Analysis of Imatinib Drugs in United States by Regions
 - 2.3.1 Market Analysis of Imatinib Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Imatinib Drugs in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Imatinib Drugs in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Imatinib Drugs in The West 2013-2017
 - 2.3.5 Market Analysis of Imatinib Drugs in The South 2013-2017
 - 2.3.6 Market Analysis of Imatinib Drugs in Southwest 2013-2017
- 2.4 Market Development Forecast of Imatinib Drugs in United States 2018-2023
 - 2.4.1 Market Development Forecast of Imatinib Drugs in United States 2018-2023
 - 2.4.2 Market Development Forecast of Imatinib Drugs by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole United States Market Status by Types
 - 3.1.1 Consumption Volume of Imatinib Drugs in United States by Types
 - 3.1.2 Revenue of Imatinib Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Imatinib Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Imatinib Drugs in United States by Downstream Industry

4.2 Demand Volume of Imatinib Drugs by Downstream Industry in Major Countries

4.2.1 Demand Volume of Imatinib Drugs by Downstream Industry in New England

4.2.2 Demand Volume of Imatinib Drugs by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Imatinib Drugs by Downstream Industry in The Midwest

4.2.4 Demand Volume of Imatinib Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Imatinib Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Imatinib Drugs by Downstream Industry in Southwest

4.3 Market Forecast of Imatinib Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF IMATINIB DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Imatinib Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 IMATINIB DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Imatinib Drugs in United States by Major Players

6.2 Revenue of Imatinib Drugs in United States by Major Players

6.3 Basic Information of Imatinib Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Imatinib Drugs Major Players

6.3.2 Employees and Revenue Level of Imatinib Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 IMATINIB DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Apotex Inc.

7.1.1 Company profile

7.1.2 Representative Imatinib Drugs Product

7.1.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Apotex Inc.

7.2 Novartis

7.2.1 Company profile

7.2.2 Representative Imatinib Drugs Product

7.2.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Novartis

7.3 Sanofi S.A.

7.3.1 Company profile

7.3.2 Representative Imatinib Drugs Product

7.3.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

7.4 Cipla Inc.

7.4.1 Company profile

7.4.2 Representative Imatinib Drugs Product

7.4.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Cipla Inc.

7.5 Mylan Pharms Inc.

7.5.1 Company profile

7.5.2 Representative Imatinib Drugs Product

7.5.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Mylan Pharms Inc.

7.6 Glenmark Pharmaceuticals Ltd.

7.6.1 Company profile

7.6.2 Representative Imatinib Drugs Product

7.6.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Glenmark

Pharmaceuticals Ltd.

7.7 Sun Pharmaceuticals

7.7.1 Company profile

7.7.2 Representative Imatinib Drugs Product

7.7.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Sun Pharmaceuticals

7.8 Actavis Generics

7.8.1 Company profile

7.8.2 Representative Imatinib Drugs Product

7.8.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Actavis Generics

7.9 Dr. Reddy's Laboratories

- 7.9.1 Company profile
- 7.9.2 Representative Imatinib Drugs Product
- 7.9.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Dr. Reddy's Laboratories
- 7.10 Teva Pharmaceutical Industries Ltd.
 - 7.10.1 Company profile
 - 7.10.2 Representative Imatinib Drugs Product
 - 7.10.3 Imatinib Drugs Sales, Revenue, Price and Gross Margin of Teva Pharmaceutical Industries Ltd.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF IMATINIB DRUGS

- 8.1 Industry Chain of Imatinib Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF IMATINIB DRUGS

- 9.1 Cost Structure Analysis of Imatinib Drugs
- 9.2 Raw Materials Cost Analysis of Imatinib Drugs
- 9.3 Labor Cost Analysis of Imatinib Drugs
- 9.4 Manufacturing Expenses Analysis of Imatinib Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF IMATINIB DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Imatinib Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/I005A61CCA5EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I005A61CCA5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970